Evidence map›Paper›PMID 41079989›Full record

ArticleGastroenterology report2025

Genetic heterogeneity and key driver mutations in the preneoplastic and earliest stages of gastric cancer.

Eduardo Alfonso Marroquín-Estrada, Héctor Martínez-Gregorio, Clara Estela Díaz-Velásquez, Fernando Ambriz-Barrera, Eduardo Emilio Córdoba-García, Laura Itzel Hernández-Romero, Miguel Ruiz De-La-Cruz, Armando Cáceres, Elisa Hernández, José Rodolfo Gil and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Eduardo Alfonso Marroquín-EstradaSchool of Postgraduate Studies, Faculty of Medical Sciences, University of San Carlos of Guatemala, Guatemala City, Guatemala.
Héctor Martínez-GregorioNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Clara Estela Díaz-VelásquezNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Fernando Ambriz-BarreraNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Eduardo Emilio Córdoba-GarcíaNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Laura Itzel Hernández-RomeroNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Miguel Ruiz De-La-CruzNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.
Armando CáceresFaculty of Chemical Sciences and Pharmacy, University of San Carlos, Guatemala City, Guatemala.
Elisa HernándezSchool of Postgraduate Studies, Faculty of Medical Sciences, University of San Carlos of Guatemala, Guatemala City, Guatemala.
José Rodolfo GilDepartment of Clinical Laboratories and Pathology, Roosevelt Hospital, Guatemala City, Guatemala.
Elizabeth OrellanaDepartment of Pathology, Francisco Marroquin Medical School, Guatemala City, Guatemala.
Daniel PenadosBIOLAB Laboratory, Guatemala City, Guatemala.
Carolina RichterBIOLAB Laboratory, Guatemala City, Guatemala.
Marcelino DíazGastroenterology Unit, Roosevelt Hospital, Guatemala City, Guatemala.
Felipe Vaca-PaniaguaNational Laboratory of Health, Molecular Diagnosis and Environmental Effects on Chronic-Degenerative Diseases, Faculty of Higher Studies Iztacala, Tlalnepantla, State of Mexico, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Gastric cancer (GC) is the fifth-leading cause of cancer-related mortality, with a 5-year survival rate less than 20%. It develops from preneoplastic lesions to adenocarcinoma, but these early genetic alterations remain poorly understood. Therefore, we aimed to identify early genetic drivers underlying the development of preneoplastic lesions and the initiation of gastric carcinogenesis. Methods: We characterized preneoplastic and early gastric adenocarcinoma using 48 samples from 16 Guatemalan patients, a country with a high incidence of GC. We sequenced a panel of 127 genes to identify early genetic drivers and possible actionable targets. Results: We identified extensive genetic heterogeneity, including single nucleotide and copy number variations. After comparing our data with other studies, we identified Conclusions: We show that at the preneoplastic and earliest stages, GC is genetically heterogeneous and presents key cancer-driving mutations that may participate in neoplastic transformation and progression, with 62.5% of lesions having the potential for treatment. This study expands the limited research on early GC and highlights key opportunities for precision medicine in populations with high GC incidence.

Indexed as

chronic gastritisearly cancer driversgastric adenocarcinomagermline variantspreneoplastic lesionssomatic variants

Identifiers

PMID41079989
PMCPMC12509836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.